Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

1-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results of the REPRISE II Study.

Meredith IT, Walters DL, Dumonteil N, Worthley SG, Tchétché D, Manoharan G, Blackman DJ, Rioufol G, Hildick-Smith D, Whitbourn RJ, Lefèvre T, Lange R, Müller R, Redwood S, Feldman TE, Allocco DJ, Dawkins KD.

JACC Cardiovasc Interv. 2016 Feb 22;9(4):376-84. doi: 10.1016/j.jcin.2015.10.024.

2.

One-Year Outcomes in "Real-World" Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS]).

Kandzari DE, Amjadi N, Caputo C, Rowe SK, Williams J, Tamboli HP, Christen T, Allocco DJ, Dawkins KD.

Am J Cardiol. 2016 Feb 15;117(4):539-45. doi: 10.1016/j.amjcard.2015.11.043. Epub 2015 Dec 7.

PMID:
26732420
3.

Response to letters regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".

Garratt KN, Weaver WD, Jenkins RG, Pow TK, Mauri L, Kereiakes DJ, Winters KJ, Christen T, Allocco DJ, Lee DP.

Circulation. 2015 Sep 29;132(13):e166-7. doi: 10.1161/CIRCULATIONAHA.115.016779. No abstract available.

PMID:
26416639
4.

Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial.

Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, Feldman RL, Stein B, Dubois C, Grady T, Saito S, Kimura T, Christen T, Allocco DJ, Dawkins KD.

Circ Cardiovasc Interv. 2015 Apr;8(4). pii: e002372. doi: 10.1161/CIRCINTERVENTIONS.114.002372.

5.

Long-term follow-up of the platinum chromium TAXUS Element (ION) stent: The PERSEUS Workhorse and Small Vessel trial five-year results.

Kereiakes DJ, Cannon LA, Dauber I, Ball M, Bertolet B, Foster M, Nersesov AY, Underwood PL, Allocco DJ, Dawkins KD.

Catheter Cardiovasc Interv. 2015 Nov 15;86(6):994-1001. doi: 10.1002/ccd.25877. Epub 2015 Feb 25.

PMID:
25678402
6.

PLATINUM China: a prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions.

Gao R, Han Y, Yang Y, Zhang J, Hou Y, Wang H, Li H, Fang Q, Yu B, Xu B, Allocco DJ, Dawkins KD.

Catheter Cardiovasc Interv. 2015 Mar;85 Suppl 1:716-23. doi: 10.1002/ccd.25859. Epub 2015 Feb 18.

PMID:
25631909
7.

Primary endpoint results of the OMEGA Study: One-year clinical outcomes after implantation of a novel platinum chromium bare metal stent.

Wang JC, Carrié D, Masotti M, Erglis A, Mego D, Watkins MW, Underwood P, Allocco DJ, Hamm CW.

Cardiovasc Revasc Med. 2015 Mar;16(2):65-9. doi: 10.1016/j.carrev.2014.12.007. Epub 2014 Dec 23.

PMID:
25576273
8.

One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE).

Tamburino C, Capodanno D, Erglis A, Menown IB, Horváth IG, Moreno R, Gilbert TJ, Crowley JJ, Calabria P, Allocco DJ, Dawkins KD.

EuroIntervention. 2015 Mar;10(11):1261-6. doi: 10.4244/EIJY15M01_01.

9.

Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.

Garratt KN, Weaver WD, Jenkins RG, Pow TK, Mauri L, Kereiakes DJ, Winters KJ, Christen T, Allocco DJ, Lee DP.

Circulation. 2015 Jan 6;131(1):62-73. doi: 10.1161/CIRCULATIONAHA.114.013570. Epub 2014 Nov 16.

10.

Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study.

Meredith Am IT, Walters DL, Dumonteil N, Worthley SG, Tchétché D, Manoharan G, Blackman DJ, Rioufol G, Hildick-Smith D, Whitbourn RJ, Lefèvre T, Lange R, Müller R, Redwood S, Allocco DJ, Dawkins KD.

J Am Coll Cardiol. 2014 Sep 30;64(13):1339-48. doi: 10.1016/j.jacc.2014.05.067.

11.

Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions.

Teirstein PS, Meredith IT, Feldman RL, Rabinowitz AC, Cannon LA, Lee TC, Dens J, Dubois CL, Mooney MR, Pompili VJ, Saito S, Allocco DJ, Dawkins KD, Stone GW.

Catheter Cardiovasc Interv. 2015 Feb 1;85(2):207-15. doi: 10.1002/ccd.25565. Epub 2014 Jul 4.

PMID:
24905795
12.

Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial).

Meredith IT, Teirstein PS, Bouchard A, Carrié D, Möllmann H, Oldroyd KG, Hall J, Allocco DJ, Dawkins KD, Stone GW.

Am J Cardiol. 2014 Apr 1;113(7):1117-23. doi: 10.1016/j.amjcard.2013.12.011. Epub 2014 Jan 14.

PMID:
24530167
13.

Japanese and non-Japanese patient outcomes in the PLATINUM randomized trial comparing the PROMUS Element and XIENCE V everolimus-eluting stents.

Saito S, Hagiwara N, Seki A, Igarashi K, Muramatsu T, Yajima J, Yokoi H, Nakamura M, Fujii K, Isshiki T, Stone GW, Teirstein PS, Meredith IT, Allocco DJ, Dawkins KD.

J Cardiol. 2014 Aug;64(2):105-12. doi: 10.1016/j.jjcc.2013.12.003. Epub 2014 Jan 23.

14.

Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study.

Meredith IT, Worthley SG, Whitbourn RJ, Antonis P, Montarello JK, Newcomb AE, Lockwood S, Haratani N, Allocco DJ, Dawkins KD.

EuroIntervention. 2014 Mar 20;9(11):1264-70. doi: 10.4244/EIJV9I11A216.

15.

Boston Scientific Lotus valve.

Meredith IT, Hood KL, Haratani N, Allocco DJ, Dawkins KD.

EuroIntervention. 2012 Sep;8 Suppl Q:Q70-4. doi: 10.4244/EIJV8SQA12.

PMID:
22995115
16.

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.

Meredith IT, Verheye S, Weissman NJ, Barragan P, Scott D, Valdés Chávarri M, West NE, Kelbæk H, Whitbourn R, Walters DL, Kubica J, Thuesen L, Masotti M, Banning A, Sjögren I, Stables RH, Allocco DJ, Dawkins KD.

EuroIntervention. 2013 Jul;9(3):308-15. doi: 10.4244/EIJV9I3A52.

17.

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.

Meredith IT, Verheye S, Weissman NJ, Barragan P, Scott D, Chávarri MV, West NE, Kelbæk H, Whitbourn R, Walters DL, Kubica J, Thuesen L, Masotti M, Banning A, Sjögren I, Stables RH, Allocco DJ, Dawkins KD.

EuroIntervention. 2013 May 22. pii: 20130416-02. [Epub ahead of print]

PMID:
23688934
18.

Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials.

Kereiakes DJ, Popma JJ, Cannon LA, Kandzari DE, Kimmelstiel CD, Meredith IT, Teirstein PS, Verheye S, Allocco DJ, Dawkins KD, Stone GW.

EuroIntervention. 2012 Jun 20;8(2):187-95. doi: 10.4244/EIJV8I2A32.

19.

Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.

Meredith IT, Verheye S, Dubois CL, Dens J, Fajadet J, Carrié D, Walsh S, Oldroyd KG, Varenne O, El-Jack S, Moreno R, Joshi AA, Allocco DJ, Dawkins KD.

J Am Coll Cardiol. 2012 Apr 10;59(15):1362-70. doi: 10.1016/j.jacc.2011.12.016. Epub 2012 Feb 15.

20.

PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses.

Meredith IT, Whitbourn R, Scott D, El-Jack S, Zambahari R, Stone GW, Teirstein PS, Starzyk RM, Allocco DJ, Dawkins KD.

EuroIntervention. 2011 May;7(1):84-90. doi: 10.4244/EIJV7I1A15.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk